MAPK3 and melanoma: A study in BRAFi+MEKi-resistant melanoma by using etoposide to re-induce pyroptosis, inhibition of the ERK1/2 pathway, and cleavage of GSDME-induced pyroptosis produced a more potent antitumor immune response, overcoming treatment resistance.470 It is suggested that targeting this regulated cell death pathway represents a potential strategy for salvage treatment of patients with BRAFi + MEKI resistant melanoma.